Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Director | September 22, 2026 | September 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date September 22, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,564 |
Reported balance
After 2026-09-22 transaction · row 1
1 source rowRow 1 · 2026-09-22 · Sale · Disposed 6,430 · Balance 19,564 F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 23, 2026 21:40 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 6,430 | $23.00 | $147,890.00 |
DisclosureSEC source: 0002048467-26-000007 · form4-09232026_090948.xml · nonDerivative · entry 1 Jones Christy · CIK 0002048467 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,564 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 20:32 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,406 | $15.00 | $21,090.00 |
DisclosureSEC source: 0002048467-26-000005 · form4-06252026_080626.xml · nonDerivative · entry 1 Jones Christy · CIK 0002048467 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,994 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:05 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 2,811 | $14.00 | $39,354.00 |
DisclosureSEC source: 0002048467-26-000004 · form4-06052026_060601.xml · nonDerivative · entry 1 Jones Christy · CIK 0002048467 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,400 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026. Read SEC document |
| May 21, 2026 Filed May 26, 2026 22:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 16,965 | $0.00 | $0.00 |
DisclosureSEC source: 0002048467-26-000003 · form4-05262026_060530.xml · nonDerivative · entry 2 Jones Christy · CIK 0002048467 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,211 F2 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| May 21, 2026 Filed May 26, 2026 22:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,998 | $9.95 | $19,880.10 |
DisclosureSEC source: 0002048467-26-000003 · form4-05262026_060530.xml · nonDerivative · entry 1 Jones Christy · CIK 0002048467 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,246 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 3,997 | $0.00 | $0.00 |
DisclosureSEC source: 0002048467-26-000002 · form4-01142026_080105.xml · nonDerivative · entry 1 Jones Christy · CIK 0002048467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,244 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 00:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 11,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008537 · form4-03182025_080310.xml · nonDerivative · entry 1 Jones Christy · CIK 0002048467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,247 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantDirector Stock Option (right to buy) · Derivative | 48,730 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001415889-25-002818 · form4-02032025_080208.xml · derivative · entry 3 Jones Christy · CIK 0002048467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,730 Underlying: Common Stock · 48,730 shares Expires 2032-07-26 F4 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from July 27, 2022. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantDirector Stock Option (right to buy) · Derivative | 9,137 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001415889-25-002818 · form4-02032025_080208.xml · derivative · entry 2 Jones Christy · CIK 0002048467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,137 Underlying: Common Stock · 9,137 shares Expires 2031-12-07 F3 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from July 20, 2021. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantDirector Stock Option (right to buy) · Derivative | 9,137 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001415889-25-002818 · form4-02032025_080208.xml · derivative · entry 1 Jones Christy · CIK 0002048467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,137 Underlying: Common Stock · 9,137 shares Expires 2031-12-07 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from April 27, 2021. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.